Construction and characterization of a reovirus double temperature-sensitive mutant

Rearranged genomic RNA segments offer a new approach to the reverse genetics of rotaviruses

Group A rotaviruses (RV), members of the Reoviridae family, are a major cause of infantile acute gastroenteritis. The RV genome consists of 11 double-stranded RNA segments. In some cases, an RNA segment is replaced by a rearranged RNA segment, which is derived from its standard counterpart by partial sequence duplication. We report here a reverse genetics system for RV based on the preferential packaging of rearranged RNA segments. Using this system, wild-type or in vitro-engineered forms of rearranged segment 7 from a human rotavirus (encoding the NSP3 protein), derived from cloned cDNAs and transcribed in the cytoplasm of COS-7 cells with the help of T7 RNA polymerase, replaced the wild-type segment 7 of a bovine helper virus (strain RF). Recombinant RF viruses (i.e., engineered monoreassortant RF viruses) containing an exogenous rearranged RNA were recovered by propagating the viral progeny in MA-104 cells, with no need for additional selective pressure. Our findings offer the possibility to extend RV reverse genetics to segments encoding nonstructural or structural proteins for which no potent selective tools, such as neutralizing antibodies, are available. In addition, the system described here is the first to enable the introduction of a mutated gene expressing a modified nonstructural protein into an infectious RV. This reverse genetics system offers new perspectives for investigating RV protein functions and developing recombinant live RV vaccines containing specific changes targeted for attenuation.

Modification of mammalian reoviruses for use as oncolytic agents

The Reoviridae are a family of viruses with a non-enveloped icosahedral capsid and a segmented double-stranded RNA genome. Prototypes of the mammalian Orthoreoviruses have been isolated from human respiratory and enteric tracts and are not associated with human disease. One of these, human reovirus type 3 Dearing (T3D), usually serves as a model for the family. In the last decade the mammalian Orthoreoviruses, especially T3D, have been evaluated as oncolytic agents in experimental cancer therapy. This is based on the observation that reoviruses induce cell death and apoptosis in tumor cells, but not in healthy non-transformed cells. Several clinical trials have been initiated in Canada, the USA, and the UK, to study the feasibility and safety of this approach. Due to the segmented structure of their double-stranded RNA genomes genetic modification of Reoviridae has been notoriously difficult. Several techniques have been described recently that facilitate the genetic modification of reovirus genomes. The basis for reverse genetics of reovirus is the discovery in 1990 that reovirus RNA is infectious. Subsequently, it took ten years before a foreign gene was introduced into the reovirus genome. Here we review the methods for reovirus modification and their use for generating new reovirus-derived oncolytic agents.

Features of the mammalian orthoreovirus 3 Dearing l1 single-stranded RNA that direct packaging and serotype restriction

A series of recombinant mammalian orthoreoviruses (mammalian orthoreovirus 3 Dearing, MRV-3De) were generated that express an MRV-3De lambda3-CAT fusion protein. Individual viruses contain L1CAT double-stranded (ds) RNAs that range in length from a minimum of 1020 bp to 4616 bp. The engineered dsRNAs were generated from in vitro-transcribed single-stranded (ss) RNAs and incorporated into infectious virus particles by using reverse genetics. In addition to defining the sequences required for these ssRNAs to be 'identified' as l1 ssRNAs, the individual nucleotides in these regions that 'mark' each ssRNA as originating from mammalian orthoreovirus 1 Lang (MRV-1La), mammalian orthoreovirus 2 D5/Jones (MRV-2Jo) or MRV-3De have been identified. A C at position 81 in the MRV-1La 5' 129 nt sequence was able to be replaced with a U, as normally present in MRV-3De; this toggled the activity of the MRV-1La ssRNA to that of an MRV-3De 5' l1. RNA secondary-structure predictions for the 5' 129 nt of both the biologically active MRV-3De l1 ssRNA and the U81-MRV-3De-restored MRV-1La 5' ssRNA predicted a common structure.

A plasmid-based reverse genetics system for animal double-stranded RNA viruses

Mammalian orthoreoviruses (reoviruses) are highly tractable experimental models for studies of double-stranded (ds) RNA virus replication and pathogenesis. Reoviruses infect respiratory and intestinal epithelium and disseminate systemically in newborn animals. Until now, a strategy to rescue infectious virus from cloned cDNA has not been available for any member of the Reoviridae family of dsRNA viruses. We report the generation of viable reovirus following plasmid transfection of murine L929 (L) cells using a strategy free of helper virus and independent of selection. We used the reovirus reverse genetics system to introduce mutations into viral capsid proteins σ1 and σ3 and to rescue a virus that expresses a green fluorescent protein (GFP) transgene, thus demonstrating the tractability of this technology. The plasmid-based reverse genetics approach described here can be exploited for studies of reovirus replication and pathogenesis and used to develop reovirus as a vaccine vector.

[Establishment of a reverse genetics system for rotavirus]

The rotavirus genome is composed of 11 segments of double-stranded RNA (dsRNA). Rotavirus is the leading etiological agent of severe gastroenteritis in infants and young children worldwide. Reverse genetics is the powerful and ideal methodology for the molecular study of virus replication, which enables the virus genome to be artificially manipulated. Very recently, we developed the first reverse genetics system for rotavirus, which enables one to generate an infectious rotavirus containing a novel gene segment derived from cDNA. In this review, we describe each steps of rotavirus replication to understand the background to the establishment of a reverse genetics system for rotavirus, and summarize the reverse genetics systems for segmented dsRNA viruses including rotavirus.

The use of monoreassortants and reverse genetics to map reovirus lysis of a ras-transformed cell line

Reovirus has been shown to lyse most transformed cells while establishing a persistent or abortive infection in non-transformed cells. Developing methods to identify the reovirus genes associated with oncolysis is an important step toward understanding the mechanisms involved. This report is the first to develop and apply the use of monoreassortants and reverse genetics to identify an individual reovirus gene associated with reovirus oncolysis. Infection with reovirus serotypes 1/Lang, 2/Jones or 3/Dearing of cells transformed with a normal copy of c-Ha-RAS (N1 cells) or with a normal copy of c-Myc (Myc-3 cells), produces large amounts of progeny virus of all three serotypes and results in lysis of both these cell lines. Infection of cells transformed with a mutant c-Ha-RAS gene (T1 cells) with either serotype 1/Lang and 2/Jones results in the production of large amounts of virus and lysis of the cells. In sharp contrast, serotype 3/Dearing virus infection of these cells produced small amounts of virus and resulted in limited lysis of these cells. Using monoreassortants and reverse genetics we exploited this phenotypic difference between the three serotypes to identify a single reovirus gene linked to the preferential lysis of the T1 cells, the S4 gene.

Reverse genetics systems of segmented double-stranded RNA viruses including rotavirus

The rotavirus genome is composed of 11 segments of double-stranded (ds)RNA. Recent studies have elucidated the precise mechanisms in transcription and replication of rotavirus RNA mainly by in vitro experiments. However, the ideal methodology for the molecular study of rotavirus replication is reverse genetics, which enables the viral genome to be artifically manipulated. Since the development of the first reverse genetics system for RNA virus in bacteriophage QB in 1978, the methodology has been developed for a variety of RNA viruses with plus-strand, minus-strand or dsRNA as a genome. However, there have been no reports on the reverse genetics of the viruses in the family Reoviridae with a genome of 10–12 segmented dsRNA, except for reovirus. This review describes the replication cycle of rotavirus with the aim of providing a general background to the development of rotavirus reverse genetics, and summarizes the reverse genetics system for dsRNA viruses, including rotavirus.

Localizing the reovirus packaging signals using an engineered m1 and s2 ssRNA

Using in vitro engineered and transcribed reovirus m1 and s2 ssRNAs, we demonstrate that the nucleotides used to identify these ssRNAs are localized to the 5' and not the 3' termini. To demonstrate this, we used our previously reported S2-CAT reovirus and we report the creation of an engineered M1-CAT reovirus. The M1 gene of this virus retains 124 nucleotides from the wild type M1 gene preceding the CAT gene and 172 nucleotides from the wild type gene following the CAT gene. The engineered M1-CAT ssRNA is 1048 nucleotides in length, much shorter than the wild type M1 at 2304 nucleotides. We have used a set of chimeric s2.m1 ssRNAs to localize the packaging signals within these RNAs. By packaging signals we mean that the presence of these signals in engineered ssRNAs results in these ssRNAs being replicated to dsRNA and packaged into progeny virus. An engineered ssRNA with a 5' sequence identical with the wild type s2 ssRNA, supported by a 3' sequence from either the m1 or s2 ssRNA, is incorporated into a virus as an S2 dsRNA. Likewise, an ssRNA with an m1 5' end is incorporated as an M1 dsRNA.

Establishment of a reverse genetics system for rotavirus: a multisegmented, double-stranded RNA virus

Evaluation of: Komoto S, Sasaki J, Taniguchi K: Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus. Proc. Natl Acad. Sci. USA 103, 4646–4651 (2006).

Rotavirus (RV), a double-stranded RNA virus within the Reoviridae family, is one of the most common causes of severe diarrhea in infants and young children worldwide. RV infections are highly contagious and may lead to severe dehydration and even death. Although vaccinations represent the most promising method for preventing RV disease in children, molecular virological techniques, such as reverse genetics, which provide a powerful tool not only for generating live-attenuated vaccines or vaccine vectors, but also for understanding gene functions and pathogenesis, are limited in the research field of RV. Komoto and colleagues have developed a novel reverse genetics system for RV using a traditional T7 RNA polymerase expression system. By using a strong selection method with neutralizing monoclonal antibodies specific for the helper RV strain KU VP4 protein, a KU-based transfectant RV carrying the strain SA11 VP4 segment, which is derived from the T7 RNA polymerase-driven plasmid, was recovered. The establishment of this system will provide a greater understanding of the molecular biology of RVs, including their replication and pathogenesis, as well as a tool for the development of attenuated vaccines or vaccine vectors.

Reverse genetics system for introduction of site-specific mutations into the double-stranded RNA genome of infectious rotavirus

We describe here the successful establishment of a reverse genetics system for rotavirus (RV), a member of the Reoviridae family whose genome consists of 10-12 segmented dsRNA. The system is based on the recombinant vaccinia virus T7 RNA polymerase-driven procedure for supplying artificial viral mRNA in the cytoplasm. With the aid of helper virus (human RV strain KU) infection, intracellularly transcribed full-length VP4 mRNA of simian RV strain SA11 resulted in the rescue of the KU-based transfectant virus carrying the SA11 VP4 RNA segment derived from cDNA. In addition to the rescued transfectant virus with the authentic SA11 VP4 gene, three more infectious RV transfectants, into which silent mutation(s) were introduced to destroy both or one of the two restriction enzyme sites as gene markers in the SA11 VP4 genome, were also rescued with this method. The ability to artificially manipulate the RV genome will greatly increase the understanding of the replication and the pathogenicity of RV and will provide a tool for the design of attenuated vaccine vectors.

The 3' sequences required for incorporation of an engineered ssRNA into the Reovirus genome

BACKGROUND

Understanding how an organism replicates and assembles a multi-segmented genome with fidelity previously measured at 100% presents a model system for exploring questions involving genome assortment and RNA/protein interactions in general. The virus family Reoviridae, containing nine genera and more than 200 members, are unique in that they possess a segmented double-stranded (ds) RNA genome. Using reovirus as a model member of this family, we have developed the only functional reverse genetics system for a member of this family with ten or more genome segments. Using this system, we have previously identified the flanking 5' sequences required by an engineered s2 ssRNA for efficient incorporation into the genome of reovirus. The minimum 5' sequence retains 96 nucleotides and contains a predicted sequence/structure element. Within these 96 nucleotides, we have identified three nucleotides A-U-U at positions 79-81 that are essential for the incorporation of in vitro generated ssRNAs into new reovirus progeny viral particles. The work presented here builds on these findings and presents the results of an analysis of the required 3' flanking sequences of the s2 ssRNA.

RESULTS

The minimum 3' sequence we localized retains 98 nucleotides of the wild type s2 ssRNA. These sequences do not interact with the 5' sequences and modifications of the 5' sequences does not result in a change in the sequences required at the 3' end of the engineered s2 ssRNA. Within the 3' sequence we discovered three regions that when mutated prevent the ssRNA from being replicated to dsRNA and subsequently incorporated into progeny virions. Using a series of substitutions we were able to obtain additional information about the sequences in these regions. We demonstrate that the individual nucleotides from, 98 to 84, 68 to 59, and 28 to 1, are required in addition to the total length of 98 nucleotides to direct an engineered reovirus ssRNA to be replicated to dsRNA and incorporated into a progeny virion. Extensive analysis using a number of RNA structure-predication software programs revealed three possible structures predicted to occur in all 10 reovirus ssRNAs but not predicted to contain conserved individual nucleotides that we could probe further by using individual nucleotide substitutions. The presence of a conserved structure would permit all ten ssRNAs to be identified and selected as a set, while unique nucleotides within the structure would direct the set to contain 10 unique members.

CONCLUSION

This study completes the characterization and mapping of the 5' and 3' sequences required for an engineered reovirus s2 ssRNA to be incorporated into an infectious progeny virus and establishes a firm foundation for additional investigations into the assortment and encapsidation mechanism of all 10 ssRNAs into the dsRNA genome of reovirus. As researchers build on this work and apply this system to additional reovirus genes and additional dsRNA viruses, a complete model for genome assortment and replication for these viruses will emerge.

Assignment of avian reovirus temperature-sensitive mutant recombination groups B, C, and D to genome segments

We recently generated a new set of avian orthoreovirus (ARV) temperature-sensitive (ts) mutants after chemical mutagenesis of wild-type strain ARV138 and described mutants in the A recombination group. Here, each prototype ts mutant from ARV recombination groups B, C, and D was crossed with wild-type ARV strain 176 to generate reassortant clones that were used to map the ts lesions in the respective mutants. Reassortant clones were identified by comparison of segment mobility to parental markers in polyacrylamide gels. An efficiency of plating (EOP) value, which measures the capacity of a virus clone to grow under non-permissive conditions, was used to assign reassortant clones to either a ts group or non-ts group. Analysis of EOP values and parental origin of genome segments in the reassortant clones revealed that the group B lesion in tsB31 was located on the M2 genome segment; the group C lesion in tsC37 was on the S3 genome segment; and the group D lesion in tsD46 was on the L2 genome segment. The assignments of tsB31 and tsC37 were further confirmed by sequence analysis and amino acid substitutions in the corresponding muB and sigmaB proteins localized within the recently determined homologous mammalian reovirus mu1/sigma3 heterohexameric crystal structure.

Identification of the 5' sequences required for incorporation of an engineered ssRNA into the Reovirus genome

Using a reovirus reverse genetics system, we have identified the 5' sequences required of an engineered s2 ssRNA for efficient incorporation into the dsRNA genome of Reovirus. Employing an engineered, functionally active reovirus S2/CAT gene retaining the first 198 5' terminal nucleotides and the last 284 3' terminal nucleotides of the wild-type S2 segment, we have determined the 5' sequence required by a ssRNA to be recognized, replicated to dsRNA, and stably incorporated into an infectious reovirus. The 5' sequence retains 96 nucleotides of the wild-type s2 ssRNA and a predicted sequence-structure element. Within these 96 nucleotides, we have identified three nucleotides A-U-U at positions 79-81 that are essential for the incorporation of in vitro-generated ssRNAs into new reovirus progeny viral particles. This study establishes a firm foundation for additional investigation into the assortment and encapsidation mechanism of all 10 ssRNAs into the dsRNA genome of reovirus.

Avian reovirus temperature-sensitive mutant tsA12 has a lesion in major core protein sigmaA and is defective in assembly

Members of our laboratory previously generated and described a set of avian reovirus (ARV) temperature-sensitive (ts) mutants and assigned 11 of them to 7 of the 10 expected recombination groups, named A through G (M. Patrick, R. Duncan, and K. M. Coombs, Virology 284:113-122, 2001). This report presents a more detailed analysis of two of these mutants (tsA12 and tsA146), which were previously assigned to recombination group A. The capacities of tsA12 and tsA146 to replicate at a variety of temperatures were determined. Morphological analyses indicated that cells infected with tsA12 at a nonpermissive temperature produced approximately 100-fold fewer particles than cells infected at a permissive temperature and accumulated core particles. Cells infected with tsA146 at a nonpermissive temperature also produced approximately 100-fold fewer particles, a larger proportion of which were intact virions. We crossed tsA12 with ARV strain 176 to generate reassortant clones and used them to map the temperature-sensitive lesion in tsA12 to the S2 gene. S2 encodes the major core protein sigmaA. Sequence analysis of the tsA12 S2 gene showed a single alteration, a cytosine-to-uracil transition, at nucleotide position 488. This alteration leads to a predicted amino acid change from proline to leucine at amino acid position 158 in the sigmaA protein. An analysis of the core crystal structure of the closely related mammalian reovirus suggested that the Leu(158) substitution in ARV sigmaA lies directly under the outer face of the sigmaA protein. This may cause a perturbation in sigmaA such that outer capsid proteins are incapable of condensing onto nascent cores. Thus, the ARV tsA12 mutant represents a novel assembly-defective orthoreovirus clone that may prove useful for delineating virus assembly.

Patterns of epistasis in RNA viruses: a review of the evidence from vaccine design

Epistasis results when the fitness effects of a mutation change depending on the presence or absence of other mutations in the genome. The predictions of many influential evolutionary hypotheses are determined by the existence and form of epistasis. One rich source of data on the interactions among deleterious mutations that has gone untapped by evolutionary biologists is the literature on the design of live, attenuated vaccine viruses. Rational vaccine design depends upon the measurement of individual and combined effects of deleterious mutations. In the current study, we have reviewed data from 29 vaccine-oriented studies using 14 different RNA viruses. Our analyses indicate that (1) no consistent tendency towards a particular form of epistasis exists across RNA viruses and (2) significant interactions among groups of mutations within individual viruses occur but are not common. RNA viruses are significant pathogens of human disease, and are tractable model systems for evolutionary studies--we discuss the relevance of our findings in both contexts.

Reovirus reverse genetics: Incorporation of the CAT gene into the reovirus genome

We have modified the infectious reovirus RNA system so as to generate a reovirus reverse genetics system. The system consists of (i) the plus strands of nine wild-type reovirus genome segments; (ii) transcripts of the genetically modified cDNA form of the tenth genome segment; and (iii) a cell line transformed so as to express the protein normally encoded by the tenth genome segment. In the work described here, we have generated a serotype 3 reovirus into the S2 double-stranded RNA genome segment of which the CAT gene has been cloned. The virus is stable, replicates in cells that have been transformed (so as to express the S2 gene product, protein final sigma 2), and expresses high levels of CAT activity. This technology can be extended to members of the orbivirus and rotavirus genera. This technology provides a powerful system for basic studies of double-stranded RNA virus replication; a nonpathogenic viral vector that replicates to high titers and could be used for clinical applications; and a system for providing nonselectable viral variants (the result of mutations, insertions, and deletions) that could be valuable for the construction of viral vaccine strains against human and animal pathogens.